Anti Venom Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Global Anti Venom Drugs Market Insights and it is Segmented by Species (Snake, Scorpion, Spiders, and Other Species), Anti-venom Type (Polyvalent Anti-venoms, Monovalent Anti-venom, and Other Anti-venom Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD million) for all the above segments.

Anti-Venom Market Size

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Anti-Venoms Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 8.54 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Anti-venom Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Anti-Venom Market Analysis

The anti-venom market is expected to register a CAGR of nearly 8.54% during the forecast period.

During the COVID-19 epidemic, there was a considerable increase in the number of deaths reported from snake bites in a few regions. This caused a significant need for anti-venoms. However, shifting priorities due to the pandemic in already vulnerable health systems impacted snakebite care on all levels. According to the study published in the British Medical Journal in October 2021, after the COVID-19 pandemic was proclaimed in 2020, an estimated 2.7 million cases of snakebite envenoming (SBE) caused over 100,000 fatalities and 400,000 long-term impairments across Asia, Africa, and Latin America's poorest and most rural communities. Such studies greatly highlighted the treatment gap amid the outbreak. On the other hand, the market is expected to grow at a stable pace in the post-pandemic phase with the emerging strains of the SARS-CoV-2 virus worldwide. For instance, according to the study published by Cold Spring Herber Laboratory in January 2022, snake venom phospholipases A2 were found to have high virucidal activity against SARS-CoV-2 in vitro and to prevent cell fusion mediated by spike glycoprotein binding with the ACE2 receptor. Thus, as per the analysis, such instances are likely to augment the demand for anti-venoms among COVID-19 patients, in turn propelling the market's growth over the forecast period.

The studied market growth can largely be attributed to factors such as the increasing awareness of anti-venoms available in the market, the surge in cases of venomous bites, and technological advancements. Snakebite is one of the most neglected public health issues in many tropical and subtropical countries. According to the May 2021 update by the WHO, approximately 5.4 million snake bites occur each year, resulting in up to 2.7 million envenomings (poisonings from snake bites) and about 81,000 to 138,000 deaths. Moreover, it often leads to around three times as many amputations and other permanent disabilities. According to the August 2022 report "Accidental Deaths & Farm Suicides in India," 10,450 snakebite cases were reported in India in 2021, with 10,382 individuals dying and 64 injured. Furthermore, the data indicated that in 2021, Madhya Pradesh scored first in terms of snake bite deaths (2,732), followed by Odisha (1,019), Chhattisgarh (909), and Uttar Pradesh (844). Thus, the growing incidence of snake bites is expected to increase demand for anti-venom treatment, thereby boosting the growth of the market.

Furthermore, the prevalence of venomous bites and stings has increased over the years. To cater to the demand for anti-venom drugs, market players are opting for many initiatives to strengthen their market presence. For instance, in September 2021, a partnership between Papua New Guinea (PNG) and Australia to donate anti-venom and help save the lives of people bitten or stung by venomous snakes and marine creatures was extended for a further two years, 2021-2023. This will increase the accessibility of anti-venomous drugs across countries, thus driving the market growth.

However, anti-venom production is difficult and expensive. The cost of anti-venom has increased over the last two decades, making treatment unaffordable for most people. This is expected to hinder market growth over the forecast period.

Anti-Venom Market Trends

This section covers the major market trends shaping the Anti-venom Market according to our research experts:

The Polyvalent Anti-venoms Segment is Expected to Hold Significant Share in the Market Over the Forecast Period

Polyvalent anti-venoms consist of antibodies that are capable of counteracting several homologous venoms from various species/genera. Polyvalent snake antivenom contains the active ingredients brown snake antivenom, tiger snake antivenom, death adder antivenom, taipan antivenom, and black snake antivenom. Polyvalent antivenoms can save the lives of victims of snake envenomation, even when the culprit snake is unknown and a monovalent antivenom cannot be chosen. Due to the obvious advantages that they have, polyvalent anti-venoms are the most preferred anti-venom drug.

Polyvalent anti-venoms are beneficial in regions where there is a large presence of venomous species and when it is difficult to produce monovalent anti-venoms against all of them. Owing to the numerous advantages, the key players dealing in the anti-venom market are focusing on developing polyvalent anti-venoms.

Furthermore, rising research and development activities proving the efficacies of existing treatments are further expected to drive the studied segment. For instance, according to the study published in Toxin Basel in October 2021, two Indian polyvalent anti-venoms, VINS and Bharat, showed positive results in preventing or reversing in vitro myotoxicity induced by common cobra (Naja naja) venom from Sri Lanka and hence can be proactively used as a therapeutic in treating cobra bites.

As a result of the aforementioned factors, such as the advantages of polyvalent anti-venom and expanding research and development activities, the segment's growth is expected to accelerate over the forecast period. 

Anti-venom Market - Number of Clinical Trials for Anti-venom, By Phase, Global, As of November 2022

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The North American anti-venom market is expected to hold a significant share during the forecast period, owing to the high incidence of snake bites and other venomous bites in the region, the rise in awareness of venomous bites, and rising technological advancements. The United States within North America is expected to contribute significantly to the market growth in the region. As per the June 2021 article by the CDC, each year, an estimated 7,000-8,000 people are bitten by venomous snakes in the United States, and about five of those people die. Workers are far more likely to suffer long-term injuries from snake bites than to die from them. Thus, due to the high prevalence of snake bites in the country, the demand for its therapeutics is expected to increase, thereby boosting the market's growth.

Moreover, product approvals and strategic initiatives by key market players are also expected to augment market growth in the country. For instance, in March 2022, Ophirex, Inc., announced that the US FDA had granted Fast Track designation to varespladib-methyl ("oral varespladib") for the treatment of snakebite. Ophirex is currently conducting a clinical trial of oral varespladib, its lead investigational drug candidate, as a broad-spectrum snakebite antidote in the United States and India.

Furthermore, in April 2021, Rare Disease Therapeutics, Inc. announced that the US FDA approved a new expanded indication for ANAVIP (crotalidae immune F(ab')2 (equine)), an equine-derived antivenin, for the management of adult and pediatric patients with North American pit viper envenomation.

Thus, due to the above-mentioned factors, such as the high prevalence of snake bites and strategic initiatives by market players, the market in the North American region is expected to witness strong growth over the forecast period.

Anti-venom Market - Growth Rate by Region

Anti-Venom Industry Overview

The anti-venom market is competitive, and consists of several market players. Most developing countries with established biotechnological facilities have local scientific expertise, which creates favorable conditions and the atmosphere to establish local anti-venom manufacturing practices. Countries such as Brazil, Costa Rica, Egypt, France, India, Mexico, South Africa, and Thailand have large, well-established anti-venom manufacturers. The major market players operating in the anti-venom market include BTG PLC, Pfizer Inc., Merck KGaA (Sigma Aldrich), Boehringer Ingelheim, and CSL Limited, among others.

Anti-Venom Market Leaders

  1. Pfizer Inc.

  2. Merck KGaA (Sigma Aldrich)

  3. Boehringer Ingelheim

  4. CSL Limited

  5. Bharat Serums and Vaccines Ltd

*Disclaimer: Major Players sorted in no particular order

Anti-venom Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Anti-Venom Market News

  • In July 2022, the foundation of the Antivenom Research and Development Centre (AVRDC) was laid at the Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru Helix Biotech Park, Electronics City, to boost the production activities for antivenom.
  • In April 2022, the complementary agreement to the technical cooperation agreement between Brazil and the government of the Republic of the Union of Myanmar for the implementation of the project "Improving methodologies and techniques for the production of antivenom serum in Myanmar - phase II: antivenom quality" was signed. The goal of the project is to increase the quality and performance of the antivenom serum produced in that Asian country.

Anti-Venom Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness on Anti-venoms Available

      2. 4.2.2 Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Complexities Involved in the Preparation of the Correct Immunogens

      2. 4.3.2 Lack of Regulatory Capacity for the Control of Anti-venoms in Countries

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 5.1 By Species

      1. 5.1.1 Snake

      2. 5.1.2 Scorpion

      3. 5.1.3 Spiders

      4. 5.1.4 Other Species

    2. 5.2 By Anti-venom Type

      1. 5.2.1 Polyvalent Anti-venoms

      2. 5.2.2 Monovalent Anti-venom

      3. 5.2.3 Other Anti-venom Types

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bharat Serums and Vaccines Ltd

      2. 6.1.2 Boehringer Ingelheim International GmbH

      3. 6.1.3 Boston Scientific Corporation

      4. 6.1.4 CSL Limited

      5. 6.1.5 Flynn Pharma Ltd (Micropharm)

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Merck KGaA (Sigma Aldrich)

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 Rare Disease Therapeutics Inc.

      10. 6.1.10 South African Vaccine Producers (Pty) Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Anti-Venom Industry Segmentation

As per the scope of the report, An anti-venom (or antivenin or antivenene) is a biological product used to treat venomous bites or stings. The anti-venom is created by extracting venom from the relevant species of animal, which includes snakes, spiders, insects, fish, etc. The Anti-venom Market is Segmented by Species (Snake, Scorpion, Spiders, and Other Species), Anti-venom Type (Polyvalent Anti-venoms, Monovalent Anti-venom, and Other Anti-venom Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecasts in value (USD million) for the above segments.

By Species
Snake
Scorpion
Spiders
Other Species
By Anti-venom Type
Polyvalent Anti-venoms
Monovalent Anti-venom
Other Anti-venom Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Anti-Venom Market Research FAQs

The Anti-venom Market is projected to register a CAGR of 8.54% during the forecast period (2024-2029)

Pfizer Inc., Merck KGaA (Sigma Aldrich), Boehringer Ingelheim, CSL Limited and Bharat Serums and Vaccines Ltd are the major companies operating in the Anti-venom Market.

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Anti-venom Market.

The report covers the Anti-venom Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Anti-venom Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Anti Venom Industry Report

Statistics for the 2024 Anti Venom market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anti Venom analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Anti Venom Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)